Atrial fibrillation (AF) is an arrhythmia that can occur as the result of numerous different pathophysiological processes in the atria. Some aspects of the morphological and electrophysiological alterations promoting AF have been studied extensively in animal models. Atrial tachycardia or AF itself shortens atrial refractoriness and causes loss of atrial contractility. Aging, neurohumoral activation, and chronic atrial stretch due to structural heart disease activate a variety of signaling pathways leading to histological changes in the atria including myocyte hypertrophy, fibroblast proliferation, and complex alterations of the extracellular matrix including tissue fibrosis. These changes in electrical, contractile, and structural properties of the atria have been called "atrial remodeling." The resulting electrophysiological substrate is characterized by shortening of atrial refractoriness and reentrant wavelength or by local conduction heterogeneities caused by disruption of electrical interconnections between muscle bundles. Under these conditions, ectopic activity originating from the pulmonary veins or other sites is more likely to occur and to trigger longer episodes of AF. Many of these alterations also occur in patients with or at risk for AF, although the direct demonstration of these mechanisms is sometimes challenging. The diversity of etiological factors and electrophysiological mechanisms promoting AF in humans hampers the development of more effective therapy of AF. This review aims to give a translational overview on the biological basis of atrial remodeling and the proarrhythmic mechanisms involved in the fibrillation process. We pay attention to translation of pathophysiological insights gained from in vitro experiments and animal models to patients. Also, suggestions for future research objectives and therapeutical implications are discussed.

Abstract-Studies on patients and large animal models suggest the importance of atrial fibrosis in the development of atrial fibrillation (AF). To investigate whether increased fibrosis is sufficient to produce a substrate for AF, we have studied cardiac electrophysiology (EP) and inducibility of atrial arrhythmias in MHC-TGFcys 33 ser transgenic mice (Tx), which have increased fibrosis in the atrium but not in the ventricles. In anesthetized mice, wild-type (Wt) and Tx did not show significant differences in surface ECG parameters. With transesophageal atrial pacing, no significant differences were observed in EP parameters, except for a significant decrease in corrected sinus node recovery time in Tx mice. Burst pacing induced AF in 14 of 29 Tx mice, whereas AF was not induced in Wt littermates (PϽ0.01). In Langendorff perfused hearts, atrial conduction was studied using a 16-electrode array. Epicardial conduction velocity was significantly decreased in the Tx RA compared with the Wt RA. In the Tx LA, conduction velocity was not significantly different from Wt, but conduction was more heterogeneous. Action potential characteristics recorded with intracellular microelectrodes did not reveal differences between Wt and Tx mice in either atrium. Thus, in this transgenic mouse model, selective atrial fibrosis is sufficient to increase AF inducibility. Key Words: atrial fibrillation Ⅲ fibrosis Ⅲ growth factors A trial fibrillation (AF) is a commonly occurring arrhythmia, present in Ϸ5% of people older than age 65 years. Clinically, increased vulnerability to AF is also associated with underlying heart disease, such as congestive heart failure (CHF) and mitral valve disease. 1 Increased inducibility of AF has been observed in animal models of aging, 2,3 CHF, 4 atrial tachycardia-induced cardiomyopathy, 5,6 and chronic atrial dilatation caused by mitral regurgitation. 7 Theoretical models have implicated atrial interstitial fibrosis as a substrate for AF. 8,9 Atrial interstitial fibrosis increases with age in humans and has been observed in patients with AF 10,11 and in animal models of aging, 2,3 mitral regurgitation, 7 and CHF. 4 With the unknown cause of atrial fibrosis in humans and the presence of compounding factors in animal models, the contribution of atrial fibrosis to AF substrate formation remains unclear. Studies to date have been limited by lack of animal models of selective atrial fibrosis to study the effects of fibrosis without the presence of heart failure or other underlying heart disease.The purpose of this study was to determine the effect of atrial fibrosis on the AF vulnerability. We have studied a transgenic mouse model with cardiac overexpression of a constitutively active form of transforming growth factor (TGF)-␤1, MHC-TGFcys 33 ser. 12 This model has been previously demonstrated to have elevated TGF-␤1 activity in the atria and ventricles. Cardiac development and morphology appear normal, except for increased interstitial fibrosis in the atrial myocardium. Ventricular size and histology is no...

Background-Intergenic variations on chromosome 4q25, close to the PITX2 transcription factor gene, are associated with atrial fibrillation (AF). We therefore tested whether adult hearts express PITX2 and whether variation in expression affects cardiac function. Methods and Results-mRNA for PITX2 isoform c was expressed in left atria of human and mouse, with levels in right atrium and left and right ventricles being 100-fold lower. In mice heterozygous for Pitx2c (Pitx2c), left atrial Pitx2c expression was 60% of wild-type and cardiac morphology and function were not altered, except for slightly elevated pulmonary flow velocity. Isolated Pitx2c ϩ/Ϫ hearts were susceptible to AF during programmed stimulation. At short paced cycle lengths, atrial action potential durations were shorter in Pitx2c ϩ/Ϫ than in wild-type. Perfusion with the ␤-receptor agonist orciprenaline abolished inducibility of AF and reduced the effect on action potential duration. Spontaneous heart rates, atrial conduction velocities, and activation patterns were not affected in Pitx2c ϩ/Ϫ hearts, suggesting that action potential duration shortening caused wave length reduction and inducibility of AF. Expression array analyses comparing Pitx2c ϩ/Ϫ with wild-type, for left atrial and right atrial tissue separately, identified genes related to calcium ion binding, gap and tight junctions, ion channels, and melanogenesis as being affected by the reduced expression of Pitx2c.Conclusions-These findings demonstrate a physiological role for PITX2 in the adult heart and support the hypothesis that dysregulation of PITX2 expression can be responsible for susceptibility to AF. (Circ Cardiovasc Genet. 2011;4:123-133.)Key Words: action potentials Ⅲ atrium Ⅲ fibrillation Ⅲ genes Ⅲ transgenic mice Ⅲ genetic predisposition A trial fibrillation (AF) is by far the most common sustained arrhythmia and causes important morbidity and mortality. 1,2 Unfortunately, the causes of the arrhythmia are not sufficiently understood to allow effective therapy to prevent AF. 3,4 Both rare and common forms of AF can be heritable, and the genes responsible may provide important clues toward therapy. Familial forms of AF associate with mutations in genes encoding sodium and potassium ion channels, connexin40, the natriuretic peptide precursor A (NPPA) but also transcription factor genes, either in candidate or genome-wide association studies. 3,[5][6][7][8] Editorial see p 105 Clinical Perspective on p 133A polymorphic locus on chromosome 4q25 (SNP rs2200733) associates with AF, particularly of early onset, in several independent studies of European and Asian populations 9,10 and conveys an approximately 1.7-fold risk of developing AF. 11 This locus is intergenic, with the gene in closest proximity being PITX2, which encodes a homeobox transcription factor of the paired type. Mutations of PITX2 are responsible for autosomal dominant anterior eye defects, including the Axenfeld-Rieger syndrome, 12 albeit without reports of AF in affected patients.During embryonic development in ...